13th Edition of International Conference on Neurology and Brain Disorders
October 19-21, 2026
Rare and Complex Brain Disorders
Rare and complex brain disorders present unique challenges for clinicians and researchers due to their heterogeneous nature and the limited understanding of their underlying mechanisms. These disorders, including conditions like cortical dysplasia, rare forms of epilepsy, and neurodegenerative diseases, often require specialized care and treatment plans tailored to the specific needs of each patient. Despite their rarity, the impact of these disorders on patients and their families can be profound, leading to significant physical, cognitive, and emotional challenges. Advances in research are beginning to unravel the genetic and molecular foundations of these conditions, offering hope for the development of more effective therapies. Early detection, better diagnostic tools, and innovative treatments, such as gene therapy and neurostimulation, are paving the way for improved outcomes and quality of life for individuals with rare brain disorders.
Ken Ware
NeuroPhysics Therapy Institute and Research Centre, Australia
Yong Xiao Wang
Albany Medical College, United States
Joe Sam Robinson
Mercer University, United States
Daniel Curry
Texas Children’s Hospital, United States
Steven Benvenisti
Davis, Saperstein Salomon, PC, United States
Andrzej Stanislaw Cieplak
Independent researcher, United States
Younok Dumortier Shin
OnusBio, United StatesSubmit your abstract Today
Title : Atypical presentation of Juvenile myoclonic epilepsy in a 16-year-old female: A case report
George Diaz, Memorial Healthcare Systems, United States
Title : Triple-network dysfunction, ME/CFS, and the NeuroPhysics Treatment Process “A dynamical systems perspective on psychophysical organization and environmental interaction”
Ken Ware, NeuroPhysics Therapy Institute and Research Centre, Australia
Title : Beyond plaques: 10-nanometer-scale pathoconnectomics of Alzheimer’s disease
Ons M Saad, Panluminate Inc., United States
Title : Results from the global phase 3 trial (IB1001-303) evaluating levacetylleucine in children and adults with ataxia-telangiectasia
Chidinma Ejim, IntraBio, United States
Title : A phase 3, multinational, randomized, placebo-controlled, double-blind, crossover trial (IB1001-304) evaluating levacetylleucine in CACNA1A
Chidinma Ejim, IntraBio, United States
Title : Clinical and molecular phenotype of PTRHD1-associated juvenile parkinsonism
Bhavan A Modi, Barrow Neurological Institute at Phoenix Children's, United States